相似文献
1
Practical management and assessment of primary plasma cell leukemia in the novel agent era.
Cancer Treat Res Commun. 2021;28:100414. doi: 10.1016/j.ctarc.2021.100414. Epub 2021 Jun 8.
2
Primary plasma cell leukemia: autologous stem cell transplant in an era of novel induction drugs.
Bone Marrow Transplant. 2019 Jul;54(7):1089-1093. doi: 10.1038/s41409-018-0392-1. Epub 2018 Nov 16.
3
Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy.
Mayo Clin Proc. 2021 Mar;96(3):677-687. doi: 10.1016/j.mayocp.2020.06.060.
4
Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience.
Leukemia. 2012 Jan;26(1):158-9. doi: 10.1038/leu.2011.176. Epub 2011 Jul 29.
5
First reported case of leukocytapheresis in plasma cell leukemia.
Transfusion. 2020 Jan;60(1):11-12. doi: 10.1111/trf.15564. Epub 2019 Nov 4.
6
Novel Agents for the Treatment of Primary Plasma-Cell Leukemia: Lights and Shadows.
Acta Haematol. 2016;135(2):110-2. doi: 10.1159/000441345. Epub 2015 Oct 28.
7
First-line treatment and survival of newly diagnosed primary plasma cell leukemia patients in the Netherlands: a population-based study, 1989-2018.
Blood Cancer J. 2021 Feb 4;11(2):22. doi: 10.1038/s41408-021-00415-5.
8
[Plasma cell leukemia in a 65 year old patient].
Wiad Lek. 1990 Jul 15;43(14):742-5.
9
Real-world data on prognosis and outcome of primary plasma cell leukemia in the era of novel agents: a multicenter national study by the Greek Myeloma Study Group.
Blood Cancer J. 2018 Mar 9;8(3):31. doi: 10.1038/s41408-018-0059-6.
10
Melphalan/total body irradiation-conditioned myeloablative allogeneic hematopoietic cell transplantation for patients with primary plasma cell leukemia.
Clin Lymphoma Myeloma Leuk. 2014 Dec;14(6):e225-8. doi: 10.1016/j.clml.2014.07.012. Epub 2014 Aug 2.
引用本文的文献
1
Primary Plasma Cell Leukemia: Recent Advances in Molecular Understanding and Treatment Approaches.
Int J Mol Sci. 2025 Jun 26;26(13):6166. doi: 10.3390/ijms26136166.
2
Changing lanes: extending CAR T-cell therapy to high-risk plasma cell dyscrasias.
Front Immunol. 2025 Apr 8;16:1558275. doi: 10.3389/fimmu.2025.1558275. eCollection 2025.
3
Survival Outcomes of Patients with Primary Plasma Cell Leukemia in the Era of Proteasome Inhibitors and Immunomodulatory Agents: A Real-Life Multicenter Analysis.
Turk J Haematol. 2024 Dec 2;41(4):225-235. doi: 10.4274/tjh.galenos.2024.2023.0450. Epub 2024 Nov 6.
4
Evolving progress in the management of malignant plasma cell disorders.
Cancer Treat Res Commun. 2022;32:100612. doi: 10.1016/j.ctarc.2022.100612. Epub 2022 Jul 19.
本文引用的文献
1
Clinical Characteristics and Outcomes of Patients With Primary Plasma Cell Leukemia in the Era of Novel Agent Therapy.
Mayo Clin Proc. 2021 Mar;96(3):677-687. doi: 10.1016/j.mayocp.2020.06.060.
2
Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): primary analysis of a randomised, phase 2 trial.
Lancet Haematol. 2021 Jan;8(1):e45-e54. doi: 10.1016/S2352-3026(20)30354-9. Epub 2020 Dec 22.
3
Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial.
Lancet Oncol. 2020 Oct;21(10):1317-1330. doi: 10.1016/S1470-2045(20)30452-6. Epub 2020 Aug 28.
4
Covid-19: Herd immunity is "unethical and unachievable," say experts after report of 5% seroprevalence in Spain.
BMJ. 2020 Jul 7;370:m2728. doi: 10.1136/bmj.m2728.
5
Primary Plasma Cell Leukemia: Real-World Retrospective Study of 46 Patients From a Single-Center Study in China.
Clin Lymphoma Myeloma Leuk. 2020 Oct;20(10):e652-e659. doi: 10.1016/j.clml.2020.05.014. Epub 2020 May 27.
6
Longer term follow-up of the randomized phase III trial SWOG S0777: bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT).
Blood Cancer J. 2020 May 11;10(5):53. doi: 10.1038/s41408-020-0311-8.
7
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study.
Lancet Haematol. 2020 Jun;7(6):e456-e468. doi: 10.1016/S2352-3026(20)30099-5. Epub 2020 Apr 30.
8
Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial.
Blood. 2020 Aug 20;136(8):936-945. doi: 10.1182/blood.2020005288.
9
Hematopoietic cell transplantation utilization and outcomes for primary plasma cell leukemia in the current era.
Leukemia. 2020 Dec;34(12):3338-3347. doi: 10.1038/s41375-020-0830-0. Epub 2020 Apr 20.
10
Utilizing multiparametric flow cytometry in the diagnosis of patients with primary plasma cell leukemia.
Am J Hematol. 2020 Jun;95(6):637-642. doi: 10.1002/ajh.25773. Epub 2020 Mar 26.
Zotero 插件